NASDAQ:OVID

Ovid Therapeutics News Headlines

$3.78
-0.04 (-1.05 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.65
Now: $3.78
$3.86
50-Day Range
$2.95
MA: $3.89
$4.47
52-Week Range
$2.25
Now: $3.78
$9.40
Volume790,371 shs
Average Volume3.74 million shs
Market Capitalization$248.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

Headlines

Ovid Therapeutics (NASDAQ OVID) News Headlines Today

SourceHeadline
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Buy" by AnalystsOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 10 at 6:54 AM
BRIEF-Ovid Therapeutics Announces Closing Of Agreement With Takeda For Global Development And Commercialization Of SoticlestatBRIEF-Ovid Therapeutics Announces Closing Of Agreement With Takeda For Global Development And Commercialization Of Soticlestat
msn.com - March 30 at 1:16 PM
Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of SoticlestatOvid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat
finance.yahoo.com - March 30 at 8:16 AM
Ovid Therapeutics Inc. (NASDAQ:OVID) Short Interest UpdateOvid Therapeutics Inc. (NASDAQ:OVID) Short Interest Update
americanbankingnews.com - March 28 at 4:46 PM
News Flash: Analysts Just Made A Notable Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) ForecastsNews Flash: Analysts Just Made A Notable Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
finance.yahoo.com - March 20 at 12:45 PM
Ovid Therapeutics Inc. (NASDAQ:OVID) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesOvid Therapeutics Inc. (NASDAQ:OVID) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
nasdaq.com - March 18 at 9:14 AM
Ovid Posts Larger-Than-Feared Quarterly Loss, Revenue BeatOvid Posts Larger-Than-Feared Quarterly Loss, Revenue Beat
finance.yahoo.com - March 16 at 10:38 AM
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
finance.yahoo.com - March 15 at 8:14 AM
What Kind Of Investors Own Most Of Ovid Therapeutics Inc. (NASDAQ:OVID)?What Kind Of Investors Own Most Of Ovid Therapeutics Inc. (NASDAQ:OVID)?
finance.yahoo.com - March 10 at 2:59 PM
Ovid Therapeutics Shares Relatively Quiet, See Slightly Volume Uptick As Hearing RBC Downgraded StockOvid Therapeutics Shares Relatively Quiet, See Slightly Volume Uptick As Hearing RBC Downgraded Stock
benzinga.com - March 5 at 4:18 AM
KMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On TrevyentKMPH Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent
nasdaq.com - March 4 at 3:16 AM
Why Ovid, KemPharm, Sorrento, Aquestive Are RallyingWhy Ovid, KemPharm, Sorrento, Aquestive Are Rallying
msn.com - March 3 at 12:15 PM
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut SyndromeTakeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
finance.yahoo.com - March 3 at 7:15 AM
Central Nervous System Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030Central Nervous System Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030
finance.yahoo.com - February 26 at 10:29 AM
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - January 15 at 12:50 PM
Italy’s Angelini to buy Swiss biotech group for $1bnItaly’s Angelini to buy Swiss biotech group for $1bn
ft.com - January 3 at 8:07 PM
OVID Jul 2021 10.000 callOVID Jul 2021 10.000 call
uk.finance.yahoo.com - December 26 at 3:00 PM
OVID Jul 2021 10.000 putOVID Jul 2021 10.000 put
uk.finance.yahoo.com - December 26 at 12:23 AM
OVID Jan 2021 5.000 callOVID Jan 2021 5.000 call
uk.finance.yahoo.com - December 25 at 7:22 PM
Is OVID A Good Stock To Buy Right Now?Is OVID A Good Stock To Buy Right Now?
finance.yahoo.com - December 16 at 9:29 AM
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology IndexOvid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
finance.yahoo.com - December 16 at 9:29 AM
Ovid Therapeutics Inc Registered Shs NeutralOvid Therapeutics Inc Registered Shs Neutral
markets.businessinsider.com - December 3 at 7:37 PM
56 Stocks Moving In Wednesdays Mid-Day Session56 Stocks Moving In Wednesday's Mid-Day Session
msn.com - December 2 at 3:49 PM
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) Investigation
finance.yahoo.com - December 2 at 3:49 PM
Why Ovid Therapeutics Stock Is Imploding TodayWhy Ovid Therapeutics Stock Is Imploding Today
finance.yahoo.com - December 2 at 3:49 PM
Ovid Therapeutics misses goal in Angelman syndrome treatmentOvid Therapeutics misses goal in Angelman syndrome treatment
seekingalpha.com - December 1 at 10:14 PM
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary EndpointOvid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
finance.yahoo.com - December 1 at 5:14 PM
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
finance.yahoo.com - November 25 at 2:38 PM
Dosing underway in Capricor Therapeutics mid-stage CAP-1002 study in COVID-19Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
seekingalpha.com - November 24 at 9:22 AM
Relief/NeuroRxs RLF-100 results in 72% survival of COVID-19 patients under EAPRelief/NeuroRx's RLF-100 results in 72% survival of COVID-19 patients under EAP
seekingalpha.com - November 24 at 4:22 AM
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual CongressOvid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
markets.businessinsider.com - November 23 at 6:21 PM
Ovid Therapeutics to Present at the American Epilepsy Society (AES)  2020 Virtual CongressOvid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
finance.yahoo.com - November 23 at 6:21 PM
News for Ovid Therapeutics Inc Registered ShsNews for Ovid Therapeutics Inc Registered Shs
markets.businessinsider.com - November 23 at 1:20 PM
Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain?Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain?
nasdaq.com - November 16 at 10:27 AM
Ovid Therapeutics Inc. (NASDAQ:OVID) Analysts Just Trimmed Their Revenue Forecasts By 66%Ovid Therapeutics Inc. (NASDAQ:OVID) Analysts Just Trimmed Their Revenue Forecasts By 66%
nasdaq.com - November 16 at 10:27 AM
These Analysts Think Ovid Therapeutics Inc.s (NASDAQ:OVID) Sales Are Under ThreatThese Analysts Think Ovid Therapeutics Inc.'s (NASDAQ:OVID) Sales Are Under Threat
finance.yahoo.com - November 16 at 10:27 AM
15 Heroines review – a triumphant revoicing of Ovid15 Heroines review – a triumphant revoicing of Ovid
msn.com - November 15 at 1:09 PM
Ovid Therapeutics EPS beats by $0.14, beats on revenueOvid Therapeutics EPS beats by $0.14, beats on revenue
seekingalpha.com - November 12 at 7:50 PM
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateOvid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 12 at 7:50 PM
Encouraging COVID-19 vaccine data fails to lift Arcturus, down 4%Encouraging COVID-19 vaccine data fails to lift Arcturus, down 4%
seekingalpha.com - November 9 at 9:21 AM
Ovid Therapeutics Inc. (OVID)Ovid Therapeutics Inc. (OVID)
finance.yahoo.com - November 7 at 2:26 PM
Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 InfectionLipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
seekingalpha.com - November 6 at 1:23 PM
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara DuncanAtea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
markets.businessinsider.com - November 6 at 8:22 AM
Mateon on go with mid-stage study of antisense drug for COVID-19Mateon on go with mid-stage study of antisense drug for COVID-19
seekingalpha.com - November 4 at 7:39 AM
All Ovid-Elsie students transition to virtual learning due to nearby COVID-19 outbreaksAll Ovid-Elsie students transition to virtual learning due to nearby COVID-19 outbreaks
msn.com - November 2 at 11:21 PM
AgeX inks sublicensing pact with ImStem for cell therapy against COVID-19AgeX inks sublicensing pact with ImStem for cell therapy against COVID-19
seekingalpha.com - October 28 at 8:47 AM
Nektar Therapeutics on go with study of bempegaldesleukin in COVID-19Nektar Therapeutics on go with study of bempegaldesleukin in COVID-19
seekingalpha.com - October 27 at 8:00 AM
The Drug Industry Gets Behind FauciThe Drug Industry Gets Behind Fauci
bloomberg.com - October 25 at 12:31 AM
Mid-stage study of Appili Therapeutics favipiravir in COVID-19 underwayMid-stage study of Appili Therapeutics' favipiravir in COVID-19 underway
seekingalpha.com - October 20 at 8:11 AM
Sorrento Therapeutics down following R&D investor update on COVID-19Sorrento Therapeutics down following R&D investor update on COVID-19
seekingalpha.com - October 14 at 2:39 PM
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.